Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
"AS has a lot of explaining to do. Will he be forthcoming and honest though? That's the question."
No, he's raised 30 million, in his eyes we should all be happy (and forget that most long term holders have averages above a quid).
Should be well into phase 2 then and hopefully some very good indicators of efficacy, as already seen in the phase 1a safety study targeting random tumour types that ava6000 may not be used for.
Phase 2 will target what will be the final indications that AVA6000 will be licensed for use against so will be very interesting. That FAP paper published yesterday also backs up that the substance that cleaves dox will be in very high abundance.
I for one am very positive about the trial going forward.
There's a meeting today to vote through the 50p rex shares.
Once that's done and they are issued tomorrow it can start moving.
It's the magic of placings whatever the price of the placing is the SP sits at it until the shares are issued.
I see Derek who told us he wasn't going to post until summer is well into his disruptive trolling this weekend thank goodness for the filter button. Although it's still a green box at the end of all the threads.
Bang on DTW.
Exactly, we need a frank and truthful update. Like you I believe the trial is still going well, why would it not be?
Just a reminder from the data rns for those who would try and tell us that ava6000 has stopped working.
1. The pre|CISIONTM platform targets the release of a chemotherapy to the tumour as intended. The data show that the pre|CISIONTM modification is cleaved specifically by Fibroblast Activation Protein (FAP), an enzyme present in high concentrations in many solid tumours compared with healthy tissue. In the case of AVA6000, this targets the release of doxorubicin to the tumour microenvironment, concentrating the active cytotoxic drug within the tumor microenvironment and limiting systemic exposure to the chemotherapy.
2. AVA6000 has significantly improved the safety and tolerability of doxorubicin. A significant reduction in the frequency and severity of the known doxorubicin toxicities has been observed across the dosing range. A maximum tolerated dose has not been reached in the three-weekly dose escalation study despite dosing approximately 3.5x the normal level of doxorubicin in the highest and final dose cohort in this part of the Phase 1a study.
3. AVA6000 has shown encouraging preliminary clinical signs of anti-tumour activity. Preliminary results in the Phase 1a trial demonstrate activity of AVA6000 in patients with tumours with high FAP activity, validating the mechanism of action of AVA6000. For example, a 59-year-old male patient with Undifferentiated Pleomorphic Sarcoma (UPS) has shown a reduction in tumour volume of 65% with a duration of response >6 months and ongoing. A number of other patients with different cancer types have shown smaller ongoing reductions in tumour volume or stable disease.